DUBLIN--(BUSINESS WIRE)--
Research and Markets has announced the addition of the "Canavan Disease - Pipeline Review, H2 2016" report to their offering.
The Pharmaceutical and Healthcare latest pipeline guide Canavan Disease - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Canavan Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Canavan Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Canavan Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively. Canavan Disease.
Canavan Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/5b2rs2/canavan_disease

View source version on businesswire.com: http://www.businesswire.com/news/home/20161209005415/en/